Hospital
King County Public Hospital District No. 2
King County Public Hospital District No. 2 was paid $31.55M by Medicaid between Jan 2018 and Dec 2024, across 343 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 23% of everything it billed.
33Billing provider infoKING COUNTY PUBLIC HOSPITAL DISTRICT NO. 2
KIRKLAND, WA 98034
KIRKLAND, WA 98034
33aNPI1033174933assigned 04/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.55M
24GClaims1,036,543
24DCodes billed343
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#19 of 49
Median peer was paid$20.06M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 130,261 | $4.31M | |
| 2019 | 132,422 | $4.23M | |
| 2020 | 127,467 | $4.00M | |
| 2021 | 163,850 | $5.21M | |
| 2022 | 154,583 | $4.80M | |
| 2023 | 173,622 | $4.77M | |
| 2024incomplete | 154,338 | $4.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23% | 101,220 | 76,517 | $7.12M |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 16,187 | 13,780 | $4.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.2% | 18,928 | 17,403 | $1.96M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.1% | 27,932 | 24,842 | $1.93M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 24,346 | 21,922 | $1.52M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 7,440 | 6,965 | $1.15M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 5,346 | 4,990 | $684K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 6,501 | 6,097 | $672K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.1% | 5,868 | 5,382 | $664K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 8,694 | 7,750 | $620K |
| 59025 | Fetal non-stress test | 1.8% | 3,861 | 2,698 | $582K |
| G0378 | Hospital observation service, per hour | 1.8% | 5,068 | 4,575 | $556K |
331 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 6,287 | $553K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 2,730 | $499K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 21,667 | $466K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 2,993 | $451K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.4% | 1,802 | $431K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 3,138 | $424K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.2% | 1,980 | $363K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,439 | $252K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,671 | $242K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 10,136 | $239K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,611 | $225K |
| 64615 | <1% | 824 | $223K | |
| 70496 | <1% | 1,366 | $213K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,435 | $210K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 12,663 | $206K |
| 76642 | <1% | 2,324 | $202K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,332 | $181K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 890 | $180K |
| 93325 | <1% | 1,257 | $160K | |
| 95806 | <1% | 672 | $140K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,184 | $139K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,879 | $134K |
| 20610 | <1% | 973 | $123K | |
| 80047 | <1% | 28,744 | $122K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,777 | $118K |
| 97161 | <1% | 3,169 | $118K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,688 | $107K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,355 | $104K |
| 93971 | <1% | 1,360 | $103K | |
| 93017 | <1% | 1,528 | $96K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,840 | $93K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,939 | $85K |
| 64483 | <1% | 217 | $79K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,310 | $78K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,592 | $77K |
| 80053 | Comprehensive metabolic panel | <1% | 17,994 | $67K |
| 84484 | <1% | 15,391 | $62K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,328 | $52K |
| 77066 | Tomosynthesis, mammo | <1% | 1,743 | $49K |
| 97165 | <1% | 1,233 | $49K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 935 | $43K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,877 | $43K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,383 | $43K |
| 80076 | <1% | 18,373 | $42K | |
| 76818 | <1% | 797 | $42K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,239 | $42K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,983 | $40K |
| 20611 | <1% | 209 | $40K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 288 | $39K |
| 93975 | <1% | 605 | $37K | |
| 12001 | <1% | 171 | $36K | |
| 97162 | <1% | 1,046 | $35K | |
| 93976 | <1% | 888 | $35K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,162 | $34K |
| 70498 | <1% | 1,130 | $32K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,554 | $31K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,348 | $27K |
| 83880 | <1% | 3,840 | $26K | |
| 93970 | <1% | 321 | $26K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,374 | $26K |
| 76801 | <1% | 876 | $25K | |
| 76942 | <1% | 356 | $25K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,773 | $23K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 966 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,104 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,231 | $22K |
| 73630 | <1% | 2,861 | $22K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 153 | $21K |
| 73610 | <1% | 2,174 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,032 | $19K |
| 83605 | <1% | 3,983 | $19K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 850 | $18K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,967 | $18K |
| 71250 | <1% | 471 | $17K | |
| 73030 | <1% | 2,199 | $16K | |
| 97803 | <1% | 459 | $16K | |
| 97116 | <1% | 1,196 | $15K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,036 | $15K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,913 | $14K |
| 73110 | <1% | 1,405 | $14K | |
| 73140 | <1% | 1,068 | $14K | |
| 87040 | <1% | 1,476 | $14K | |
| 85379 | <1% | 2,885 | $14K | |
| 94060 | <1% | 926 | $12K | |
| 90715 | <1% | 747 | $12K | |
| 76820 | <1% | 348 | $11K | |
| 73130 | <1% | 1,300 | $11K | |
| 72100 | <1% | 1,249 | $11K | |
| 93226 | <1% | 597 | $11K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,387 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,704 | $11K |
| 73564 | <1% | 2,244 | $11K | |
| 82607 | <1% | 1,999 | $11K | |
| 99490 | Ccm add 20min | <1% | 564 | $11K |
| 80061 | Lipid panel | <1% | 3,894 | $10K |
| 76821 | <1% | 298 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,039 | $9K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 100 | $9K |
| 93351 | <1% | 109 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,088 | $7K |
| 84439 | <1% | 2,089 | $7K | |
| 94729 | <1% | 982 | $7K | |
| 76770 | <1% | 89 | $7K | |
| J3490 | Unclassified drugs | <1% | 1,771 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,718 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,072 | $6K |
| 93296 | <1% | 792 | $6K | |
| 73502 | <1% | 769 | $6K | |
| 94726 | <1% | 705 | $6K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $6K |
| 93308 | <1% | 24 | $5K | |
| 85027 | <1% | 2,733 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 398 | $5K |
| 20550 | <1% | 41 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $4K |
| 82728 | <1% | 769 | $4K | |
| 77080 | <1% | 79 | $4K | |
| 73562 | <1% | 184 | $4K | |
| 97035 | <1% | 712 | $4K | |
| 80143 | <1% | 1,149 | $4K | |
| 84703 | <1% | 10,814 | $4K | |
| 76813 | <1% | 106 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 783 | $4K |
| 93225 | <1% | 570 | $3K | |
| 86780 | <1% | 494 | $3K | |
| 76641 | <1% | 44 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,263 | $3K |
| 83735 | <1% | 6,227 | $3K | |
| 10061 | <1% | 13 | $3K | |
| 86140 | <1% | 4,019 | $3K | |
| 70486 | <1% | 161 | $3K | |
| 86803 | <1% | 747 | $3K | |
| 0011A | <1% | 135 | $3K | |
| 70487 | <1% | 18 | $3K | |
| 82570 | <1% | 1,685 | $3K | |
| 87070 | <1% | 2,852 | $3K | |
| 95886 | <1% | 12 | $3K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $2K |
| 85610 | <1% | 14,168 | $2K | |
| 72131 | <1% | 395 | $2K | |
| 86592 | <1% | 412 | $2K | |
| 86850 | <1% | 1,431 | $2K | |
| 84702 | <1% | 2,281 | $2K | |
| 87507 | <1% | 42 | $2K | |
| 86900 | <1% | 2,722 | $2K | |
| 81001 | <1% | 9,997 | $2K | |
| 82077 | <1% | 4,738 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,900 | $2K |
| 80179 | <1% | 1,079 | $2K | |
| 87077 | <1% | 2,404 | $2K | |
| 72110 | <1% | 210 | $2K | |
| 82962 | <1% | 9,079 | $2K | |
| 81003 | <1% | 13,197 | $1K | |
| 83690 | <1% | 12,086 | $1K | |
| 87186 | <1% | 2,645 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 159 | $1K |
| 84481 | <1% | 329 | $1K | |
| 85652 | <1% | 3,166 | $1K | |
| 73700 | <1% | 24 | $1K | |
| 83550 | <1% | 460 | $1K | |
| 87340 | <1% | 520 | $1K | |
| 76857 | <1% | 13 | $1K | |
| 87081 | <1% | 305 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,522 | $1K |
| 73080 | <1% | 154 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,126 | $1K |
| 82565 | <1% | 1,168 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 316 | $1K |
| 74018 | <1% | 176 | $1K | |
| 76937 | <1% | 19 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 75 | $1K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 836 | $1K |
| 72040 | <1% | 130 | $1K | |
| 97760 | <1% | 43 | $1K | |
| 86901 | <1% | 1,796 | $980.01 | |
| 87641 | <1% | 101 | $949.05 | |
| 90686 | <1% | 92 | $925.74 | |
| 0012A | <1% | 31 | $900.22 | |
| 82550 | <1% | 1,436 | $883.13 | |
| 73560 | <1% | 71 | $875.69 | |
| 82746 | <1% | 265 | $862.66 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 914 | $857.83 |
| 83540 | <1% | 544 | $855.69 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,192 | $835.51 |
| 87205 | <1% | 2,154 | $822.02 | |
| 86762 | <1% | 225 | $787.43 | |
| 86038 | <1% | 230 | $744.54 | |
| 84550 | <1% | 1,099 | $726.93 | |
| 84403 | <1% | 148 | $712.01 | |
| 84153 | <1% | 105 | $699.57 | |
| 36000 | <1% | 2,542 | $680.68 | |
| 82043 | <1% | 636 | $659.49 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $650.57 |
| 72128 | <1% | 175 | $648.18 | |
| 85730 | <1% | 2,419 | $617.77 | |
| 72120 | <1% | 180 | $613.11 | |
| 84100 | <1% | 963 | $588.95 | |
| 97163 | <1% | 12 | $561.22 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 33 | $546.43 |
| 82950 | <1% | 165 | $521.38 | |
| 96127 | <1% | 106 | $514.56 | |
| 82951 | <1% | 73 | $513.93 | |
| 86787 | <1% | 147 | $508.78 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,531 | $501.30 |
| 87088 | <1% | 740 | $487.23 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15,020 | $477.54 |
| 93246 | <1% | 31 | $466.95 | |
| 82105 | <1% | 59 | $463.19 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 78 | $461.52 |
| 83970 | <1% | 40 | $449.85 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,863 | $430.20 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,367 | $425.17 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 57 | $407.73 |
| 96376 | <1% | 5,757 | $399.35 | |
| 84156 | <1% | 533 | $390.75 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 887 | $369.06 |
| 84450 | <1% | 469 | $353.30 | |
| 86317 | <1% | 73 | $346.72 | |
| 64447 | <1% | 12 | $316.54 | |
| 87634 | <1% | 333 | $308.29 | |
| 84460 | <1% | 571 | $307.10 | |
| 87075 | <1% | 1,241 | $306.25 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,015 | $304.16 |
| 83001 | <1% | 43 | $277.12 | |
| 74019 | <1% | 29 | $273.17 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 26 | $266.26 |
| 86480 | <1% | 13 | $256.79 | |
| 76000 | <1% | 14 | $255.61 | |
| 86704 | <1% | 84 | $250.22 | |
| 85014 | <1% | 464 | $238.85 | |
| 90677 | <1% | 12 | $231.91 | |
| 99409 | <1% | 13 | $230.60 | |
| 80069 | <1% | 70 | $204.04 | |
| 73590 | <1% | 54 | $201.93 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 10,261 | $187.98 |
| J1815 | Injection, insulin, per 5 units | <1% | 786 | $183.24 |
| 84146 | <1% | 31 | $176.77 | |
| A9270 | Non-covered item or service | <1% | 5,384 | $175.27 |
| 85018 | <1% | 564 | $173.73 | |
| 90662 | <1% | 136 | $166.42 | |
| 82248 | <1% | 604 | $159.74 | |
| 90674 | <1% | 17 | $135.42 | |
| 81025 | <1% | 687 | $134.18 | |
| 84402 | <1% | 24 | $133.38 | |
| 84520 | <1% | 251 | $127.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,571 | $126.09 |
| 84112 | <1% | 12 | $124.36 | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,082 | $99.79 |
| 80178 | <1% | 12 | $96.69 | |
| 94664 | <1% | 143 | $94.61 | |
| 87210 | <1% | 197 | $90.88 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $84.15 |
| 72050 | <1% | 25 | $81.80 | |
| 86765 | <1% | 25 | $77.31 | |
| 83516 | <1% | 42 | $76.75 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 602 | $74.13 |
| 88304 | <1% | 228 | $71.82 | |
| 87430 | <1% | 491 | $71.73 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,159 | $66.29 |
| 86431 | <1% | 39 | $66.07 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,480 | $65.90 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 397 | $65.66 |
| 93242 | <1% | 14 | $61.41 | |
| 73660 | <1% | 12 | $57.72 | |
| 73090 | <1% | 14 | $55.79 | |
| 83002 | <1% | 12 | $54.04 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,973 | $51.20 |
| 82330 | <1% | 186 | $47.66 | |
| 80050 | General health panel | <1% | 29 | $46.37 |
| 87800 | <1% | 13 | $45.69 | |
| 0001A | <1% | 18 | $43.20 | |
| 86200 | <1% | 13 | $41.50 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,780 | $40.23 |
| 82784 | <1% | 33 | $38.89 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,247 | $35.84 |
| 81002 | <1% | 2,400 | $29.07 | |
| 97597 | <1% | 42 | $25.89 | |
| 99152 | <1% | 450 | $25.07 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,695 | $23.28 |
| 82009 | <1% | 117 | $22.60 | |
| 0352U | <1% | 318 | $22.49 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 346 | $22.27 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,489 | $20.96 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 194 | $19.60 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 154 | $18.66 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,692 | $17.58 |
| 99153 | Mod sedat endo service >5yrs | <1% | 62 | $17.54 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 225 | $13.26 |
| 84425 | <1% | 15 | $12.75 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 746 | $12.71 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 230 | $9.15 |
| 99406 | <1% | 31 | $8.56 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,840 | $7.16 |
| C1769 | Guide wire | <1% | 1,437 | $3.84 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,401 | $3.69 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 567 | $2.94 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,894 | $2.43 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 273 | $1.85 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 644 | $0.78 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,051 | $0.33 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 877 | $0.16 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 278 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 244 | $0.00 |
| 76376 | 0% | 39 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 303 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 15 | $0.00 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 113 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 414 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 70 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 129 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 45 | $0.00 |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 12 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 16 | $0.00 |
| 90653 | 0% | 55 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 49 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 82 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 388 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 160 | $0.00 |
| 87154 | 0% | 215 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 296 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 79 | $0.00 |
| 0240U | 0% | 120 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 105 | $0.00 |
| 82803 | 0% | 70 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 194 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 30 | $0.00 |
| 82150 | 0% | 17 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 15 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 16 | $0.00 |
| 93280 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOWE, WILLIAM (CFO)
Parent organizationKING COUNTY PUBLIC HOSPITAL DISTRICT NO. 2
| Provider | Location | Paid |
|---|---|---|
| King County Public Hospital District No. 2 | Kirkland, WA | $1.44M |
| King County Public Hospital District No. 2 | Redmond, WA | $1.01M |
| King County Public Hospital District No 2 | Bothell, WA | $742K |
| King County Public Hospital District No 2 | Kirkland, WA | $604K |
| King County Public Hospital District No. 2 | Kirkland, WA | $41K |
| King County Public Hospital District No 2 | Kirkland, WA | $9K |
| King County Public Hospital District No 2 | Kirkland, WA | $5K |
| King County Public Hospital District No 2 | Kirkland, WA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.